A detailed history of Bank Of America Corp transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 172,477 shares of KROS stock, worth $7.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
172,477
Previous 193,449 10.84%
Holding current value
$7.88 Million
Previous $7.69 Million 48.45%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$41.26 - $70.48 $865,304 - $1.48 Million
-20,972 Reduced 10.84%
172,477 $11.4 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $3.72 Million - $5.63 Million
137,236 Added 244.14%
193,449 $7.69 Million
Q2 2023

Aug 14, 2023

SELL
$37.26 - $51.01 $724,930 - $992,450
-19,456 Reduced 25.71%
56,213 $2.26 Million
Q1 2023

May 12, 2023

BUY
$41.44 - $59.32 $403,128 - $577,064
9,728 Added 14.75%
75,669 $3.23 Million
Q4 2022

Feb 10, 2023

BUY
$39.45 - $51.77 $506,182 - $664,260
12,831 Added 24.16%
65,941 $3.17 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $398,679 - $575,360
14,341 Added 36.99%
53,110 $2 Million
Q2 2022

Aug 12, 2022

BUY
$26.03 - $67.04 $116,614 - $300,339
4,480 Added 13.07%
38,769 $1.07 Million
Q1 2022

May 16, 2022

BUY
$42.12 - $59.36 $123,243 - $173,687
2,926 Added 9.33%
34,289 $1.86 Million
Q4 2021

Feb 08, 2022

BUY
$36.95 - $62.89 $44,931 - $76,474
1,216 Added 4.03%
31,363 $1.84 Million
Q3 2021

Nov 15, 2021

BUY
$29.27 - $43.71 $648,447 - $968,351
22,154 Added 277.17%
30,147 $1.19 Million
Q2 2021

Sep 13, 2021

BUY
$42.4 - $70.11 $338,903 - $560,389
7,993 New
7,993 $339,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.